Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of XT-150 in Osteoarthritis of the Knee
NCT04124042Phase 2Completed
- Sponsor
- Xalud Therapeutics
- Start
- Feb 2020
- Primary completion
- Apr 2022
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of XT-150 in osteoarthritis (OA) (6 arms), sponsored by Xalud Therapeutics. Primary endpoints: Number of Participants Achieving 30% Improvement From Baseline in Western Ontario and McMasters Arthritis Index (WOMAC) Pain Score at Day 180, Change From Baseline in WOMAC Pain Score at Day 180 and 2 more. Started Feb 2020; status: completed.
02
Drugs
XT-150
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04124042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04124042.